Siemens Eclipse HP Cyclotron for PET Imaging Research

描述（由申请人提供）：该提案要求为西门子Eclipse HP回旋加速器提供资金，以支持自1992年以来在匹兹堡大学运行的非常成功的正电子发射断层扫描（PET）成像研究计划。这个充满活力的研究项目目前得到了28个NIH资助的赠款以及来自匹兹堡大学医学院8个学术部门的25名研究人员的几个基金会和行业支持的研究项目的支持。该小组在出版物和转化研究方面取得了令人印象深刻的成就，例如PET/CT扫描仪和淀粉样蛋白成像剂[11 C]阿伯堡化合物B（Pi B）的开发，该化合物目前正在全球范围内用于阿尔茨海默病研究和临床试验。Eclipse HP将取代1992年安装的传统西门子RDS-112回旋加速器，该回旋加速器已被制造商宣布寿命终止，仅保留有限的可维修性。回旋加速器是任何PET研究计划的关键设备，因为大多数项目摘要中使用的放射性核素半衰期短，需要现场生产。RDS-112的失败将对正在进行的NIH资助的研究造成重大和有害的中断。除了对现有基础设施进行关键升级外，Eclipse HP系统的多项功能还将显著增强PET研究计划。Eclipse HP电磁铁的深谷设计提供了改进的光束传输，降低了内部激活水平，提高了产量，而单线圈磁体设计大大降低了功耗。所提出的Eclipse HP配置的第二个优点是使用双4位置目标转盘，总共8个目标。目前的RDS-112系统有四条固定的射束线，每条射束线只有一个固定的目标，因此限制了目标的利用。在建议的Eclipse HP配置中增加的靶数量以及双靶辐照的灵活性将代表我们放射性核素生产能力的显著提高。所要求的附件包括用于生产[11 C]MeI的远程自动气相系统和碳-11和氟-18的掺入平台，将使我们能够实现新回旋加速器的最大效率，从而实现连续放射性药物生产的快速周转时间。实现这些效率至关重要，因为RDS-112目前为两台西门子HR+ PET扫描仪和两台临床前microPET扫描仪提供放射性药物。本建议书中描述的19个主要用户项目和3个次要用户项目将受益于现代化和当前支持的回旋加速器，该回旋加速器将在可预见的未来保持PET设施的放射性药物生产能力。此外，Eclipse HP放射性核素生产能力的提高将使现有的PET扫描仪得到更充分的利用，从而提高研究产出，并将支持继续扩大该机构进行的PET成像研究的范围。 公共卫生相关性：西门子Eclipse HP回旋加速器将产生短寿命的放射性材料，以支持匹兹堡大学非常成功的正电子发射断层扫描（PET）成像研究计划，该计划目前由28个NIH资助的赠款支持，这些赠款将PET成像用于一系列疾病的新型生物医学研究。所要求的回旋加速器和附件将取代1992年安装的、供应商不再支持的遗留回旋加速器，并促进PET设施生产能力的急需增加。如果获得批准，该提案预计将对该机构（创造4-5个新工作岗位，维持40多个工作岗位）和供应商（西门子及其供应商维持75个工作岗位）的美国就业岗位产生重大影响，同时实现相当于13个普通美国家庭用电量的节能。

DESCRIPTION (provided by applicant): This proposal requests funds for a Siemens Eclipse HP Cyclotron in support of a highly successful positron emission tomography (PET) imaging research program that has been operational at the University of Pittsburgh since 1992. This vibrant research program is presently supported by 28 NIH-funded grants as well as several foundation and industry supported research projects from a group of 25 investigators from 8 academic departments of the University Of Pittsburgh School Of Medicine. This group has an impressive record of publication and achieving translational research successes such as the development of the PET/CT scanner and the amyloid imaging agent [11C]Pittsburgh-compound B (PiB) that is now being used worldwide in Alzheimer's disease research and clinical trials. The Eclipse HP will replace a legacy Siemens RDS-112 cyclotron, installed in 1992, which has been declared end-of-life by the manufacturer and retains only limited serviceability. The cyclotron is a key piece of equipment for any PET research program as the radionuclides used in a majority of the included project summaries have short half-lives that necessitate on-site production. Failure of the RDS-112 would represent a significant and detrimental interruption to ongoing NIH-sponsored research. In addition to providing a critical upgrade to existing infrastructure, several features of the Eclipse HP system will significantly enhance the PET research program. The deep-valley design of the Eclipse HP electromagnets provides improved beam transmission, reduced levels of internal activation, and higher production yields, while the single-coil magnet design drastically reduces power consumption. A second advantage of the proposed Eclipse HP configuration is the use of dual 4-position target carousels for a total of eight targets. The current RDS-112 system has four fixed beam lines, each with only one stationary target- thus limiting target utilization. The increased number of targets in the proposed Eclipse HP configuration as well as flexibility in dual target irradiation will represent a dramatic improvement in our radionuclide production capacity. The requested accessories, which include a remote automated gas-phase system for the production of [11C]MeI and incorporation platforms for both carbon-11 and fluorine-18, will allow us to realize the maximum efficiencies of the new cyclotron by enabling quick turnaround times for serial radiopharmaceutical productions. Realizing these efficiencies is of paramount importance as the RDS-112 presently supplies radiopharmaceuticals for two human Siemens HR+ PET scanners and two preclinical microPET scanners. The 19 major and 3 minor user projects described in this proposal will benefit from the sitting of a modern and currently supported cyclotron that will maintain the radiopharmaceutical production capabilities of the PET Facility for the foreseeable future. In addition, the increased radionuclide production capacity of the Eclipse HP will allow existing PET scanners to be more completely utilized, resulting in a greater output of studies, and will support continued expansion of the scope of PET imaging research conducted at the institution. PUBLIC HEALTH RELEVANCE: The Siemens Eclipse HP cyclotron requested will produce short-lived radioactive materials in support of a highly successful positron emission tomography (PET) imaging research program at the University of Pittsburgh, which is presently supported by 28 NIH funded grants that use PET imaging in novel biomedical investigations across a spectrum of diseases. The requested cyclotron and accessories will replace a legacy cyclotron installed in 1992 that is no longer supported by the vendor and facilitate a much needed increase in the PET Facility's production capacity. If awarded, this proposal is expected to have a significant impact on American jobs both at the institution (4-5 new jobs created, 40+ jobs maintained) and at the vendor (75+ jobs maintained at Siemens and its suppliers), while realizing an energy savings in terms of electricity use that is equivalent to the usage of 13 average American households.